Showing 281 - 300 results of 46,417 for search '(( 20 ((mean decrease) OR (we decrease)) ) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 1.03s Refine Results
  1. 281

    SFN decreased MMP-2 expression and activity in U87MG and U373MG cells. by Chunliu Li (284115)

    Published 2014
    “…<p>(A) SFN decreased MMP-2 expression via activated ERK1/2. We treated the cells with SFN (20 µM) without or with PD98059 (25 µM) for 24 h. …”
  2. 282
  3. 283
  4. 284
  5. 285

    DataSheet_1_Accelerating Decreases in the Incidences of Hepatocellular Carcinoma at a Younger Age in Shanghai Are Associated With Hepatitis B Virus Vaccination.docx by Shunzhang Yu (12340927)

    Published 2022
    “…Sero-epidemiological data from the sampling surveys during 20 years of follow-up showed that less than 1% of people undergoing HBV vaccination have a positive serum HBsAg. …”
  6. 286
  7. 287

    DataSheet_1_Accelerating Decreases in the Incidences of Hepatocellular Carcinoma at a Younger Age in Shanghai Are Associated With Hepatitis B Virus Vaccination.docx by Shunzhang Yu (12340927)

    Published 2022
    “…Sero-epidemiological data from the sampling surveys during 20 years of follow-up showed that less than 1% of people undergoing HBV vaccination have a positive serum HBsAg. …”
  8. 288

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  9. 289

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  10. 290

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  11. 291

    Results of mean differences. by Ekkarat Meephu (15307058)

    Published 2023
    “…A simulation was conducted to identify 20 scenarios in order to discover the optimal scenario in which where the number of requests (stretchers or wheelchairs) was increased, while the number of staff was decreased to determine mean waiting times and confidence intervals. …”
  12. 292
  13. 293
  14. 294
  15. 295
  16. 296

    Targeting <em>A20</em> Decreases Glioma Stem Cell Survival and Tumor Growth by Anita B. Hjelmeland (104655)

    Published 2010
    “…To determine the functional significance of A20 in GSCs, we targeted <em>A20</em> expression with lentiviral-mediated delivery of short hairpin RNA (shRNA). …”
  17. 297
  18. 298

    Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

    Published 2020
    “…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …”
  19. 299

    CXCL8 and CCL20 Enhance Osteoclastogenesis via Modulation of Cytokine Production by Human Primary Osteoblasts by Janak L. Pathak (759122)

    Published 2015
    “…We hypothesized that CXCL8 and CCL20 decrease osteoblast proliferation and differentiation, and enhance osteoblast-mediated osteoclast formation and activity. …”
  20. 300